Herpes Simplex Virus - HSV | Choose the Right Test

Medical Experts

Author

Leonard

Nicole Leonard, MD

Anatomic and Clinical Pathology Resident, University of Utah School of Medicine and ARUP Laboratories

Contributor

Slev

Patricia R. Slev, PhD, D(ABCC)

Professor of Pathology (Clinical), University of Utah

Section Chief, Immunology; Medical Director, Immunology Core Laboratory, ARUP Laboratories

Herpes simplex virus (HSV) is a prevalent, easily transmissible virus that causes lifelong viral infection. There are two known subtypes: herpes simplex virus type 1 (HSV-1) and HSV-2. HSV-1 can cause both oral and genital infections, but HSV-2 is the major cause of genital herpes. Classically, infections result in painful oral or genital lesions; however, symptoms are often mild or not present at all, which makes diagnosis difficult. After primary infection, HSV becomes latent in nerve roots and can reactivate, resulting in symptom recurrence and viral shedding. Neonates can be infected via vertical transmission from an infected mother during pregnancy, delivery, or during the postpartum period. HSV is also a rare but serious cause of encephalitis that can affect patients of all age groups. The recommended test for active genital herpes is viral culture or nucleic acid amplification testing (NAAT) of vesicle fluid. NAAT is the recommended testing method for neonates and for cases in which encephalitis or bloodborne infection is suspected.^, Serologic testing is performed to identify past or recent exposure to the virus but cannot determine the exact timing of exposure or the site of infection. Subtyping can be performed by NAAT or serologic testing to differentiate between HSV-1 and HSV-2 and is indicated if genital lesions are present.

Quick Answers for Clinicians

Which laboratory tests are used to confirm herpes simplex virus infection?

Virologic and serologic testing methods are available to confirm herpes simplex virus (HSV) infection. Direct detection of the virus by nucleic acid amplification testing (NAAT) or viral culture is recommended for neonates and patients who have an active infection with lesions, to test for disseminated bloodborne infection in immunocompromised patients, and for cerebrospinal fluid (CSF) testing. Serologic testing for immunoglobulin G (IgG) can be used to determine if a person has ever been exposed to HSV but cannot determine exactly when the exposure occurred or the site of infection. Type-specific serologic testing for HSV-1- and HSV-2-specific glycoproteins can determine the subtype of the virus, which provides useful information about prognosis and informs treatment and counseling.

What is the significance of type-specific herpes simplex virus testing?

Genital herpes is most often caused by herpes simplex virus type 2 (HSV-2), but HSV-1-associated cases are increasing. Recurrence and subclinical viral shedding occur more frequently in cases caused by HSV-2 than in cases caused by HSV-1, which may impact treatment and counseling decisions. Therefore, subtyping HSV using nucleic acid amplification testing (NAAT) or serology testing can guide treatment decisions and patient counseling. Subtyping may also provide epidemiologic information about transmission of the virus.

How should serology results be interpreted when herpes simplex virus type 1 and 2 immunoglobulin G antibodies are detected but type-specific glycoprotein antibodies are not?

The immunoglobulin G (IgG) antibodies that are detected with the combined assay develop days to weeks after initial exposure to herpes simplex virus (HSV). However, the glycoprotein antibodies used to differentiate between HSV type 1 (HSV-1) and HSV-2 may take up to 6 months to form. This delay in timing may result in the presence of combined IgG antibodies but a lack of type-specific glycoprotein antibodies early in HSV infection. Thus, patients who test positive for IgG antibodies but negative for both types of glycoprotein antibodies should be retested at least 1 month later.

Indications for Testing

Persons with signs or symptoms of HSV infection should be tested. Additionally, type-specific testing should be performed in persons with recurrent genital symptoms. If a patient has active lesion(s), nucleic acid amplification testing (NAAT) should be performed on a sample from a lesion. Serology testing is used in the absence of active lesions. Per the U.S. Preventive Services Task Force (USPSTF), screening of asymptomatic individuals in the general population for HSV-1 and HSV-2 is not indicated, including during pregnancy. HSV testing may be considered in patients being evaluated for a sexually transmitted infection (STI).

Laboratory Testing

Laboratory Testing for HSV
Virologic Testing (for Direct Detection of HSV Infection)
Test Methodology	Uses/Benefits	Limitations
NAAT	Preferred method of testing CSF and blood Highly sensitive and specific Rapid diagnostic testing Subtyping may be included	May yield false-negative results early in disease Data are lacking for use of NAAT to test neonatal swab samples
Viral culture	Traditional gold standard test to identify acute HSV infection in active lesions Preferred method to test samples from lesions or mucous membrane swabs in neonates High specificity Subtyping may be included	Not as sensitive as NAAT for other samples, including CSF and blood Decreases in sensitivity with disease progression, recurrent infections, and as acute lesions begin to heal May yield false-negative results later in disease
Antigen detection by DFA	Not generally preferred May be helpful to identify acute HSV infection in active lesions	Lower sensitivity Backup culture required to confirm negative or indeterminate results Typing not included
Serologic Testing
Serology, type 1 and/or 2, IgG	Confirmation of HSV exposure in the absence of active lesions	Cannot determine time of exposure or site of infection Includes antibodies to both type 1 and type 2 and cannot differentiate between them False-negative results may occur early in disease because antibodies take 10-21 days to form
Serology, type 1 and type 2 glycoprotein, IgG	Epidemiologic data collection Potentially useful in patient counseling regarding acquisition of virus May inform treatment decisions Can differentiate between type 1 and type 2	False-negative results may occur early in disease because type-specific antibodies can take an average of 2-3 wks and up to 6 mos to form Some patients never develop type-specific antibodies Cross-reactivity between subtypes may occur
Serology, IgM	Not recommended for clinical use	Lacks specificity due to cross-reactivity with other herpes viruses Results are not clinically significant
CSF, cerebrospinal fluid; DFA, direct fluorescent antibody testing; IgM, immunoglobulin M References: CDC, 2021; Strick, 2006

Diagnosis

Genital Herpes

Genital herpes is a chronic, lifelong infection. HSV-2 is the primary cause of genital herpes; however, HSV-1 is responsible for a growing number of cases. HSV can be transmitted easily and the virus can be shed even when symptoms are mild or not apparent. Most people positive for HSV-1 or HSV-2 have not been diagnosed with genital herpes and may not realize they have it.

Antivirals agents can reduce the severity and frequency of symptoms and transmission of the virus but are not curative. When indicated, treatment for HSV-1 and HSV-2 is the same. However, HSV-1 is less likely to manifest with recurrent episodes and shedding; treatment may not be indicated in some patients, and treatment decisions should be based on clinical evaluation. Infection with HSV-2 also increases the risk of acquiring HIV infection (refer to the ARUP Consult Human Immunodeficiency Virus topic and Human Immunodeficiency Virus in Adults and Adolescents Testing Algorithm).

Clinical suspicion for genital herpes should be confirmed by laboratory testing. The presentation is not specific and is often similar to the presentation of other conditions, including syphilis and chancroid. Confirming the diagnosis is important for proper patient management.

Virologic testing of samples from active lesions is the best way to confirm HSV diagnosis. NAAT has been shown to be more sensitive than culture and is the preferred diagnostic testing method. Sensitivity decreases as the disease progresses, as lesions heal, and in recurrences. A negative test in the presence of active lesions does not rule out HSV because viral shedding is intermittent.

If there are no active lesions but exposure to HSV is suspected, serologic testing may be used. IgG to HSV-1/2 develops before type-specific IgG to HSV-1 and HSV-2 glycoproteins, which take an average of 2-3 weeks and up to 6 months to develop. If the suspected exposure was particularly recent, IgG to HSV-1/2 should be tested first, with reflex to the type-specific antibodies. If the exposure was in the past, type-specific testing for IgG to HSV-1 and HSV-2 glycoproteins alone can be performed. If suspicion is high but results are negative, testing should be repeated 6-12 months later, given that false-negative results can occur, especially early in the disease. Some patients never develop type-specific antibodies. A positive IgG result cannot determine the exact time of exposure or the site of infection. IgM testing is not recommended because it is unreliable for acute infection and has been shown to cross-react with other herpes viruses.^,

Neonatal HSV

HSV can be transmitted from an infected mother to the neonate during pregnancy, during delivery, or after delivery. The risk is highest during delivery, especially if the mother acquired genital herpes near the time of delivery. All pregnant individuals should be asked whether they have a history of genital herpes. At the onset of labor, they should also be asked about symptoms and examined for lesions. Although routine screening of mothers for HSV is not recommended, serologic testing can be used to assess risk in patients with a sex partner who has a known HSV diagnosis.

Neonatal herpes infection can present as disseminated infection involving multiple organ systems, with central nervous system involvement, or with only mucocutaneous involvement. If there is clinical suspicion for HSV, specimens should be obtained for viral culture from the conjunctivae, mouth, nasopharynx, rectum, and any lesions. Viral culture is still recommended for these specimens because there are not enough data relating to use of NAAT testing in this population. CSF and blood samples, however, should be tested using NAAT. Serologic testing in neonates is not helpful, given that detected HSV IgG antibodies are most likely transplacentally acquired maternal antibodies.

HSV Encephalitis

HSV is the most common cause of nonepidemic, sporadic, acute focal encephalitis in the U.S. The majority of cases are caused by HSV-1 in adults. Without treatment, these cases of encephalitis have a high mortality rate. The clinical presentation is nonspecific and the differential diagnosis includes St. Louis encephalitis, Eastern equine encephalitis, and Epstein-Barr viruses, among others. Thus, early identification of HSV and appropriate treatment are important to the clinical course.

The recommended test for HSV encephalitis is NAAT on a CSF sample obtained by lumbar puncture. Viral culture lacks sensitivity in CSF. NAAT can be falsely negative, especially in children and early in the disease course. If NAAT is negative and there is clinical suspicion for HSV, a second lumbar puncture should be performed within 3-7 days and the CSF should be tested. Serologic testing on CSF is available but often not clinically useful.

Screening

According to the USPSTF, screening of asymptomatic individuals for HSV-1 and HSV-2 in the general population is not indicated, including during pregnancy. HSV testing may be considered for patients presenting for an STI evaluation.

Immunocompromised Patients

Immunocompromised patients, including those positive for HIV and those who have undergone transplants, can be at higher risk for more severe HSV infections. When the immune system is weakened, the ability to maintain HSV in the latent state is decreased, which results in increased frequency and severity of mucocutaneous recurrences as well as the possibility of dissemination of the disease to other organ systems. In these cases, antibody testing will not be helpful and NAAT should be used.

Antiviral Susceptibility Testing

HSV may become resistant to first-line and second-line treatment. Treatment susceptibility testing may be useful to help guide treatment when patients are not responding to medications.